2289

Treatment for Multiple Sclerosis (MS) (RA1)

Wormser Uri, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research

Immunomodulatory peptides derived from Japanese rice

Categories

Peptide, Small Molecule, Inflammatory/Autoimmune diseases

Development Stage

Proof of concept in MS mouse model

Patent Status

Patent filed in the United States

Market

Worldwide, the incidence of multiple sclerosis (MS) is approximately 0.1%. The market for MS has total global revenues of over $6 billion.

Highlights

  • Two peptides, termed IIIM1 and RA1,have found to be active in ameliorating MS symptoms in animals
  • One of these peptides, RA1, is also found in Japanese rice ( Oryza Sativa Japonica group) may be involved in the low prevalence and incidence of MS in Chinese and Japanese populations.
  • Current MS treatments are of limited efficacy and have severe/unpleasant side effects.
  • Initial toxicity tests have not revealed any side effects.

Our Innovation

  • Two synthetic peptides have found to be effective for treating or protecting against inflammatory conditions or diseases, including multiple sclerosis (MS).

Key Features

  • The two peptides are easily synthesized and can be delivered orally.
  • RA1 can be delivered both orally and intraperitoneally
  • RA1 is a naturally-occurring peptide found in Japanese rice and will thus require less stringent toxicology tests for FDA approval

Development Milestones

  • Toxicity studies, clinical trials

The Opportunity

  • Applications in the treatment of other inflammatory diseases, autoimmune diseases, and diseases associated with free radicals
  • The peptides may be used as treatments and also as adjuvants to other treatments.

 

Patent Status

Granted US 8,765,679; Europe 2558110

Contact for more information:

Shoshana Keynan
VP, Head of Business Development, Healthcare
+972-2-6586683
Contact ME:
Image CAPTCHA